Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof
EP4770630A1Pending Publication Date: 2026-07-08MAZE THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- MAZE THERAPEUTICS INC
- Filing Date
- 2024-08-28
- Publication Date
- 2026-07-08
AI Technical Summary
Technical Problem
Current treatments for phenylketonuria (PKU) and other diseases related to SLC6A19, such as metabolic syndrome and Hartnup disorder, are limited in efficacy and accessibility, necessitating the development of new therapeutic approaches.
Method used
The development of compounds that inhibit SLC6A19, specifically those of formula (I) and its variations, which modulate the activity of SLC6A19 in cells, thereby reducing the intestinal absorption and renal reabsorption of phenylalanine and other amino acids.
Benefits of technology
Inhibiting SLC6A19 with these compounds effectively reduces plasma phenylalanine levels, improves metabolic outcomes, and treats SLC6A19-mediated diseases, offering a potential therapeutic solution for conditions currently with limited treatment options.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2024044223_06032025_PF_FP_ABST
Abstract
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R1, R2, R3, R5, R6, R7, R8, R9, and R10 are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting SLC6A19 and methods of treating a SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.
Need to check novelty before this filing date? Find Prior Art